Update on the chemotherapeutic management of endometrial cancer

Clinical Advances in Hematology and Oncology

Volumn 12, Issue 10, 2014, Pages 659-665

  Bregar, Amy ^a   Robison, Katina ^a   Dizon, Don S ^b  

^a WOMEN AND INFANTS HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemotherapy; Endometrial cancer; Epothilones; MTOR inhibitors; Tyrosine kinase inhibitors

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; BRIVANIB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; GEFITINIB; IFOSFAMIDE; IXABEPILONE; LAPATINIB; MEGESTROL ACETATE; NINTEDANIB; OXALIPLATIN; PACLITAXEL; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TOPOTECAN; TRASTUZUMAB; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PROTEIN TYROSINE KINASE; TARGET OF RAPAMYCIN KINASE;

ARTERY RUPTURE; ARTICLE; BLEEDING DISORDER; CANCER CHEMOTHERAPY; CARDIOVASCULAR DISEASE; DIGESTIVE SYSTEM PERFORATION; DISEASE COURSE; ENDOMETRIUM CANCER; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; LEUKOPENIA; METABOLIC DISORDER; MULTICENTER STUDY (TOPIC); NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); THROMBOCYTOPENIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DRUG DEVELOPMENT; DRUG EFFECTS; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTOR PROTEIN-TYROSINE KINASES; TOR SERINE-THREONINE KINASES;

EID: 84908145593     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Endometrial (uterine) cancer. American Cancer Society. http://www.cancer.org/cancer/endometrialcancer/detailedguide/endometrial-uterine-cancer-keystatistics. Updated February 3, 2014. Accessed July 5, 2014.
2. Sorosky JI. Endometrial cancer. Obstet Gynecol. 2012;120(2 pt 1):383-397.
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2011. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/ csr/1975_2011/. Based on November 2013 SEER data submission. Updated May 12, 2014. Accessed July 5, 2014.
4. Maxwell GL, Tian C, Risinger J, et al; Gynecologic Oncology Group study. Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer. 2006;107(9):2197-2205.
5. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991;40(1):55-65.
6. Kodama S, Kase H, Tanaka K, Matsui K. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet. 1996;53(1):23-30.
7. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(suppl 1):S105-S143.
8. Lewin SN, Herzog TJ, Barrena Medel NI, et al. Comparative performance of the 2009 International Federation of Gynecology and Obstetrics’ staging system for uterine corpus cancer. Obstet Gynecol. 2010;116(5):1141-1149.
9. Lewin SN. Revised FIGO staging system for endometrial cancer. Clin Obstet Gynecol. 2011;54(2):215-218.
10. McMeekin DS, Yashar C, Campos SM, Zaino RJ. Corpus: epithelial tumors. In: Barakat RR, Berchuck A, Markman M, Randall ME, editors. Principles and Practice of Gynecologic Oncology. 6th ed. Philadelphia, PA: Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013;661-714.
11. Voss MA, Ganesan R, Ludeman L, et al. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer—a clinical and pathological evaluation. Gynecol Oncol. 2012;124(1):15-20.
12. Randall ME, Filiaci VL, Muss H, et al. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2006;24(1):36-44.
13. Fleming GF, Filiaci VL, Bentley RC, et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. Ann Oncol. 2004;15(8):1173-1178.
14. Homesley HD, Filiaci V, Gibbons SK, et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: a Gynecologic Oncology Group study. Gynecol Oncol. 2009;112(3):543-552.
15. Miller D, Filiaci V, Fleming G, et al. Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: a Gynecologic Oncology Group study [SGO abstract LBA-1]. Gynecol Oncol. 2012;125(3):771-773.
16. Moore KN, Tian C, McMeekin DS, Thigpen JT, Randall ME, Gallion HH. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer. 2010;116(23):5407-5414.
17. Matoda M, Omatsu K, Yamamoto A, et al. Importance of platinum-free interval in second-line chemotherapy for advanced or recurrent endometrial cancer. Eur J Gynaecol Oncol. 2014;35(3):224-229.
18. Lee FY, Covello KL, Castaneda S, et al. Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res. 2008;14(24):8123-8131.
19. Lee F, Jure-Kunkel MN, Salvati ME. Synergistic activity of ixabepilone plus other anticancer agents: preclinical and clinical evidence. Ther Adv Med Oncol. 2011;3(1):11-25.
20. Dizon DS, Blessing JA, McMeekin DS, Sharma SK, DiSilvestro P, Alvarez RD. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: Gynecologic Oncology Group trial 129-P. J Clin Oncol. 2009;27(19):3104-3108.
21. ClinicalTrials.gov. A study of ixabepilone as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (IXAMPLE2). http://clinicaltrials.gov/ct2/show/NCT00883116?term=NCT00883116. Identifier NCT00883116. Accessed July 14, 2014.
22. ClinicalTrials.gov. Paclitaxel, carboplatin, and bevacizumab or paclitaxel, carboplatin, and temsirolimus or ixabepilone, carboplatin, and bevacizumab in treating patients with stage III, stage IV, or recurrent endometrial cancer. http://clinicaltrials. gov/show/NCT00977574. Identifier NCT00977574. Accessed July 15, 2014.
23. Hecht JL, Mutter GL. Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol. 2006;24(29):4783-4791.
24. Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer [ASCO abstract 5516]. J Clin Oncol. 2007;25(18S)(suppl).
25. Oza AM, Elit L, Provencher D, et al. A phase II study of temsirolimus (CCI- 779) in patients with metastatic and/or locally advanced recurrent endometrial cancer previously treated with chemotherapy: NCIC CTG IND 160b [ASCO abstract 5516]. J Clin Oncol. 2008;26(15S)(suppl):296s.
26. Slomovitz BM, Lu KH, Johnston T, et al. A phase II study of oral mammalian target of rapamycin mTOR inhibitor, RAD001 (everolimus), in patients with recurrent endometrial carcinoma (EC) [ASCO abstract 5502]. J Clin Oncol. 2008;26(15S)(suppl):293s.
27. Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol. 2011;29(24):3278-3285.
28. Alvarez EA, Brady WE, Walker JL, et al. Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(1):22-27.
29. Fleming GF, Filiaci VL, Marzullo B, et al. Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol. 2014;132(3):585-592.
30. Myers AP. New strategies in endometrial cancer: targeting the PI3K/mTOR pathway--the devil is in the details. Clin Cancer Res. 2013;19(19):5264-5274.
31. Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2011;29(16):2259-2265.
32. Coleman RL, Sill MW, Lankes HA, et al. A phase II evaluation of aflibercept in the treatment of recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2012;127(3):538-543.
33. Powell MA, Sill MW, Goodfellow PJ, et al. A phase II trial of brivanib in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. Int J Gynecol Cancer. 2012;22(suppl 3):E115.
34. Correa R, Mackay H, Hirte HW, et al. A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia [ASCO abstract 5038]. J Clin Oncol 2010;28:15S(suppl).
35. Nimeiri HS, Oza AM, Morgan RJ, et al. A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia. Gynecol Oncol. 2010;117(1):37-40.
36. Dizon DS, Sill M, Schilder JM, et al. Results of Gynecologic Oncology Group (GOG) 229 K: a phase II trial of BIBF-1120 for women with advanced, recurrent, or metastatic endometrial carcinoma [SGO abstract 133]. Gynecol Oncol. 2014;133:55.
37. Meng X, Dizon DS, Yang S, et al. Strategies for molecularly enhanced chemotherapy to achieve synthetic lethality in endometrial tumors with mutant p53 [published online December 7, 2013]. Obstet Gynecol Int. doi:10.1155/2013/828165.
38. Sutton GP, Blessing JA, DeMars LR, Moore D, Burke TW, Grendys EC. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol. 1996;63(1):25-27.
39. Homesley HD, Blessing JA, Sorosky J, Reid G, Look KY. Phase II trial of liposomal doxorubicin at 40 mg/m(2) every 4 weeks in endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 2005;98(2):294-298.
40. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as secondline chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003;88(3):277-281.
41. Moore DH, Blessing JA, Dunton C, Buller RE, Reid GC. Dactinomycin in the treatment of recurrent or persistent endometrial carcinoma: a phase II study of the Gynecologic Oncology Group. Gynecol Oncol. 1999;75(3):473-475.
42. Muggia FM, Blessing JA, Sorosky J, Reid GC. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2002;20(9):2360-2364.
43. Miller DS, Blessing JA, Lentz SS, Waggoner S. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2002;87(3):247-251.
44. Fracasso PM, Blessing JA, Molpus KL, Adler LM, Sorosky JI, Rose PG. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2006;103(2):523-526.
45. Garcia AA, Blessing JA, Nolte S, Mannel RS; Gynecologic Oncology Group. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol. 2008;111(1):22-26.
46. Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer. 2010;116(23):5415-5419.
47. Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol. 2008;26(26):4319-4325.
48. Slomovitz B, Schmeler K, Miller D, et al. Phase II study of cetuximab (erbitux) in patients with progressive or recurrent endometrial cancer [SGO abstract 13]. Gynecol Oncol. 2010;116(13)(suppl 1).
49. Fleming GF, Sill MW, Darcy KM, et al. Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2010;116(1):15-20.
50. Leslie KK, Sill MW, Lankes HA, et al. Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer. Gynecol Oncol. 2012;127(2):345-350.
51. Leslie KK, Sill MW, Fischer E, et al. A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;129(3):486-494.